<DOC>
	<DOCNO>NCT00004862</DOCNO>
	<brief_summary>Phase I trial study effectiveness augmerosen plus fludarabine cytarabine treat patient refractory relapse acute myeloid leukemia acute lymphoblastic leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Gene therapy augmerosen may make cancer cell sensitive chemotherapy drug . Combining one drug augmerosen may kill cancer cell .</brief_summary>
	<brief_title>Augmerosen Plus Fludarabine Cytarabine Treating Patients With Refractory Relapsed Acute Myeloid Leukemia Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose fludarabine cytarabine combine augmerosen ( G3139 ) patient refractory relapse acute myeloid leukemia acute lymphoblastic leukemia recommend start dose phase II study . II . Determine qualitative quantitative toxic effect regimen patient regard organ specificity , time course , predictability , reversibility . III . Document therapeutic response patient treat regimen . IV . Measure bcl-2 related antiapoptotic proapoptotic protein circulate and/or marrow leukemia cell , , treatment G3139 . V. Measure WT1 expression leukemic blast surrogate marker minimal residual disease correlate bcl-2 related antiapoptotic proapoptotic gene expression . VI . Determine time require bcl-2 level recover treatment regimen . VII . Determine TP53 mutation present leukemic blast mutation may affect expression BAX , level treatment induced apoptosis , clinical endpoint . VIII . Assess apoptosis leukemic cell , , treatment regimen . IX . Determine pharmacokinetics fludarabine cytarabine patient treat regimen . X . Perform pharmacodynamic study fludarabine cytarabine leukemic cell patient prior treatment . OUTLINE : This dose-escalation study fludarabine cytarabine . Patients receive augmerosen IV continuously day 1-10 filgrastim ( G-CSF ) subcutaneously begin day 5 continue blood count recover . Patients receive fludarabine IV 30 minute follow 3.5 hour later cytarabine IV 4 hour day 6-10 . Patients achieve complete response ( CR ) receive second course begin 4 week completion first course . Patients achieve CR match sibling unrelated bone marrow donor may undergo allogeneic bone marrow transplantation . Cohorts 3-6 patient receive escalate dos fludarabine cytarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven refractory relapse acute myeloid leukemia acute lymphoblastic leukemia Marrow cellularity must least 20 % Must diagnostic lumbar puncture treatment prophylactic intrathecal methotrexate within 1 week prior enter study No active CNS involvement CNS involvement allow residual leukemic cell detect CSF follow intrathecal chemotherapy PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : At least 4 week Bilirubin great 2 time upper limit normal ( ULN ) ALT AST great 2 time ULN Alkaline phosphatase great 2 time ULN* Unless attributable malignancy Creatinine great 1.5 mg/dL unless attributable malignancy No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Resting cardiac ejection fraction le 45 % unless attributable malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study No history allergy study medication No uncontrolled concurrent illness No active infection No serious medical psychiatric illness would preclude informed consent limit survival le 4 week PRIOR CONCURRENT THERAPY : At least 2 week since prior chemotherapy except hydroxyurea No concurrent corticosteroid except grade 4 toxicity unresponsive agent At least 4 week since prior radiotherapy No concurrent investigational standard agent therapy leukemia</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
</DOC>